Craig-Hallum analyst Alexander Nowak maintained a Hold rating on NeuroOne Medical Technologies (NMTC – Research Report) today. The company’s shares closed last Friday at $1.45.
Nowak covers the Healthcare sector, focusing on stocks such as CVRx, QuidelOrtho, and CareDx. According to TipRanks, Nowak has an average return of 0.9% and a 40.19% success rate on recommended stocks.
Currently, the analyst consensus on NeuroOne Medical Technologies is a Moderate Buy with an average price target of $3.33.
See the top stocks recommended by analysts >>
Based on NeuroOne Medical Technologies’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $741.78 thousand and a GAAP net loss of $3.14 million. In comparison, last year the company earned a revenue of $68.79 thousand and had a GAAP net loss of $1.37 million
Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NeuroOne Medical Technologies (NMTC) Company Description:
NeuroOne Medical Technologies Corp. operates as a medical technology company. It focuses on development and commercialization of thin film electrode technology for cEEG and sEEG recording, brain stimulation and ablation solutions for patients suffering from brain related disorders. The company was founded on August 20, 2009 and is headquartered in Minnetonka, MN.
Read More on NMTC:
- Neuroone Medical Technologies Corporation (NMTC) Q1 Earnings Cheat Sheet
- NeuroOne® to Report First Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on February 13
- NeuroOne Medical price target raised to $3.33 from $2.20 at Alliance Global
- NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Corporate Update
- Options Volatility and Implied Earnings Moves Today, December 14, 2023
